HPV-related oropharyngeal cancer: a review on burden of the disease and opportunities for prevention and early detection

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi:10.3322/caac.21387.
   PubMed Web of Science ®Google Scholar
• McLaughlin-Drubin ME, Munger K. Oncogenic activities of human papillomaviruses. Virus Res. 2009;143(2):195–208. doi:10.1016/j.virusres.2009.06.008.
   PubMed Web of Science ®Google Scholar
• Ducatman BS. The role of human papillomavirus in oropharyngeal squamous cell carcinoma. Arch Pathol Lab Med. 2018;142(6):715–18. doi:10.5858/arpa.2018-0083-RA.
   PubMed Web of Science ®Google Scholar
• Munoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24(Suppl 3):S3/1–10. doi:10.1016/j.vaccine.2006.05.115.
   Web of Science ®Google Scholar
• Combes JD, Franceschi S. Role of human papillomavirus in non-oropharyngeal head and neck cancers. Oral Oncol. 2014;50(5):370–79. doi:10.1016/j.oraloncology.2013.11.004.
   PubMed Web of Science ®Google Scholar
• American cancer society: cancer facts & figures. Atlanta, GA; 2017.
   Google Scholar
• Van Dyne EA, Mona Saraiya SJH, Thomas CC, Markowitz LE, Benard VB. Trends in human papillomavirus–associated cancers — United States, 1999–2015. 2018 [accessed 2018]. https://www.cdc.gov/mmwr/volumes/67/wr/mm6733a2.htm?s_cid=mm6733a2_w.
   Google Scholar
• Jemal A, Simard EP, Dorell C, Noone A-M, Markowitz LE, Kohler B, Eheman C, Saraiya M, Bandi P, Saslow D, et al. Annual report to the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013;105(3):175–201. doi:10.1093/jnci/djs491.
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008;26(4):612–19. doi:10.1200/JCO.2007.14.1713.
   PubMed Web of Science ®Google Scholar
• Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol. 2015;33(29):3235–42. doi:10.1200/JCO.2015.61.6995.
   PubMed Web of Science ®Google Scholar
• Elrefaey S, Massaro MA, Chiocca S, Chiesa F, Ansarin M. HPV in oropharyngeal cancer: the basics to know in clinical practice. Acta Otorhinolaryngol Ital. 2014;34(5):299–309.
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK. Epidemiology and clinical aspects of HPV in head and neck cancers. Head Neck Pathol. 2012;6(Suppl 1):S16–24. doi:10.1007/s12105-012-0377-0.
   PubMedGoogle Scholar
• Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008;100(6):407–20. doi:10.1093/jnci/djn025.
   PubMed Web of Science ®Google Scholar
• Gillison ML, Alemany L, Snijders PJ, Chaturvedi A, Steinberg BM, Schwartz S, Castellsagué X. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine. 2012;30(Suppl 5):F34–54. doi:10.1016/j.vaccine.2012.05.070.
   PubMed Web of Science ®Google Scholar
• Gillison ML, Broutian T, Pickard RK, Tong ZY, Xiao W, Kahle L, Graubard BI, Chaturvedi AK. Prevalence of oral HPV infection in the United States, 2009-2010. Jama. 2012;307(7):693–703. doi:10.1001/jama.2012.101.
   PubMed Web of Science ®Google Scholar
• McIlwain WR, Sood AJ, Nguyen SA, Day TA. Initial symptoms in patients with HPV-positive and HPV-negative oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg. 2014;140(5):441–47. doi:10.1001/jamaoto.2014.141.
   PubMed Web of Science ®Google Scholar
• O‘Sullivan B, Huang SH, Su J, Garden AS, Sturgis EM, Dahlstrom K, Lee N, Riaz N, Pei X, Koyfman SA, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016;17(4):440–51. doi:10.1016/S1470-2045(15)00560-4.
   PubMed Web of Science ®Google Scholar
• Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35. doi:10.1056/NEJMoa0912217.
   PubMed Web of Science ®Google Scholar
• Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, Forastiere A, Gillison ML. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100(4):261–69. doi:10.1093/jnci/djn011.
   PubMedGoogle Scholar
• Forastiere AA. Chemotherapy in the treatment of locally advanced head and neck cancer. J Surg Oncol. 2008;97(8):701–07. doi:10.1002/jso.21012.
   PubMed Web of Science ®Google Scholar
• Ward G, Mehta V, Moore M. Morbidity, mortality and cost from HPV-related oropharyngeal cancer: impact of 2-, 4- and 9-valent vaccines. Hum Vaccin Immunother. 2016;12(6):1343–47. doi:10.1080/21645515.2015.1095415.
   PubMed Web of Science ®Google Scholar
• Tolentino Ede S, Centurion BS, Ferreira LHC, Souza APD, Damante JH, Rubira-Bullen IRF. Oral adverse effects of head and neck radiotherapy: literature review and suggestion of a clinical oral care guideline for irradiated patients. J Appl Oral Sci. 2011;19:448–54.
   PubMed Web of Science ®Google Scholar
• Irune E, Dwivedi RC, Nutting CM, Harrington KJ. Treatment-related dysgeusia in head and neck cancer patients. Cancer Treat Rev. 2014;40(9):1106–17. doi:10.1016/j.ctrv.2014.06.011.
   PubMed Web of Science ®Google Scholar
• Kocak-Uzel E, Gunn GB, Colen RR, Kantor ME, Mohamed ASR, Schoultz-Henley S, Mavroidis P, Frank SJ, Garden AS, Beadle BM, et al. Beam path toxicity in candidate organs-at-risk: assessment of radiation emetogenesis for patients receiving head and neck intensity modulated radiotherapy. Radiother Oncol. 2014;111(2):281–88. doi:10.1016/j.radonc.2014.02.019.
   PubMed Web of Science ®Google Scholar
• Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay M, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011;12(2):127–36. doi:10.1016/S1470-2045(10)70290-4.
   PubMed Web of Science ®Google Scholar
• McBride SM, Parambi RJ, Jang JW, Goldsmith T, Busse PM, Chan AW. Intensity-modulated versus conventional radiation therapy for oropharyngeal carcinoma: long-term dysphagia and tumor control outcomes. Head Neck. 2014;36(4):492–98. doi:10.1002/hed.23319.
   PubMed Web of Science ®Google Scholar
• Vatca M, Lucas JT, Laudadio J, D’Agostino RB, Waltonen JD, Sullivan CA, Rouchard-Plasser R, Matsangou M, Browne JD, Greven KM, et al. Retrospective analysis of the impact of HPV status and smoking on mucositis in patients with oropharyngeal squamous cell carcinoma treated with concurrent chemotherapy and radiotherapy. Oral Oncol. 2014;50(9):869–76. doi:10.1016/j.oraloncology.2014.06.010.
   PubMed Web of Science ®Google Scholar
• Chera BS, Amdur RJ, Tepper J, Qaqish B, Green R, Aumer SL, Hayes N, Weiss J, Grilley-Olson J, Zanation A, et al. Phase 2 trial of de-intensified chemoradiation therapy for favorable-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2015;93(5):976–85. doi:10.1016/j.ijrobp.2015.08.033.
   PubMed Web of Science ®Google Scholar
• Lorch JH, Hanna GJ, Posner MR, O’Neill A, Thotakura VL, Limaye SA, Rabinowits G, Sher DJ, Tishler RB, Haddad RI. Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: the Dana Farber Experience. Head Neck. 2016;38(Suppl 1):E1618–24. doi:10.1002/hed.24289.
   PubMed Web of Science ®Google Scholar
• Maxwell JH, Kumar B, Feng FY, Worden FP, Lee JS, Eisbruch A, Wolf GT, Prince ME, Moyer JS, Teknos TN, et al. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res. 2010;16(4):1226–35. doi:10.1158/1078-0432.CCR-09-2350.
   PubMed Web of Science ®Google Scholar
• Gillison ML, Zhang Q, Jordan R, Xiao W, Westra WH, Trotti A, Spencer S, Harris J, Chung CH, Ang KK. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol. 2012;30(17):2102–11. doi:10.1200/JCO.2011.38.4099.
   PubMed Web of Science ®Google Scholar
• Lairson DR, Wu C-F, Chan W, Dahlstrom KR, Tam S, Sturgis EM. Medical care cost of oropharyngeal cancer among texas patients. Cancer Epidemiol Biomarkers Prev. 2017;26(9):1443–49. doi:10.1158/1055-9965.EPI-17-0220.
   PubMed Web of Science ®Google Scholar
• Chesson HW, Ekwueme DU, Saraiya M, Watson M, Lowy DR, Markowitz LE. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Vaccine. 2012;30(42):6016–19. doi:10.1016/j.vaccine.2012.07.056.
   PubMed Web of Science ®Google Scholar
• Moore EJ, Hinni ML, Olsen KD, Price DL, Laborde RR, Inman JC. Cost considerations in the treatment of oropharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg. 2012;146(6):946–51. doi:10.1177/0194599812437534.
   PubMed Web of Science ®Google Scholar
• Healthy people 2020 [accessed 2018 Sept]. https://www.healthypeople.gov/node/3513/data-details.
   Google Scholar
• Chaturvedi AK, Graubard BI, Broutian T, Pickard RKL, Tong Z-Y, Xiao W, Kahle L, Gillison ML. Effect of prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV infections among young adults in the United States. J Clin Oncol. 2018;36(3):262–67. doi:10.1200/JCO.2017.75.0141.
   PubMed Web of Science ®Google Scholar
• Sexually transmitted disease surveillance 2017. [ accessed 2019 Jan 13]. https://www.cdc.gov/std/stats17/other.htm.
   Google Scholar
• Kreimer AR, Johansson M, Waterboer T, Kaaks R, Chang-Claude J, Drogen D, Tjønneland A, Overvad K, Quirós JR, González CA, et al. Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol. 2013;31(21):2708–15. doi:10.1200/JCO.2012.47.2738.
   PubMed Web of Science ®Google Scholar
• Gupta A, Perkins RB, Ortega G, Feldman S, Villa A. Barrier use during oro-genital sex and oral human papillomavirus prevalence: analysis of NHANES 2009–2014. Oral Dis. 2019;25(2):609–16.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, Bocchini JA, Unger ER. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63:1–30.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Brodszki N, van Damme P, Diez-Domingo J, Icardi G, Petersen LK, Tran C, Thomas S, Luxembourg A, Baudin M. A randomized, double-blind, phase III study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus gardasil(R) in 9-15-Year-old girls. Pediatr Infect Dis J. 2015;34(9):992–98. doi:10.1097/INF.0000000000000773.
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364(5):401–11. doi:10.1056/NEJMoa0909537.
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Isaacs-Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA, Quiterio M, Lazcano-Ponce E. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)–the MAM Study. Vaccine. 2015;33(42):5640–46. doi:10.1016/j.vaccine.2015.08.072.
   PubMed Web of Science ®Google Scholar
• Mehta V, Holmes S, Master A, Leblanc B, Caldito LG, Bocchini J. Knowledge of HPV-related oropharyngeal cancer and use of human papillomavirus vaccines by pediatricians in Louisiana. J La State Med Soc. 2017;169:37–42.
   PubMedGoogle Scholar
• Luryi AL, Yarbrough WG, Niccolai LM, Roser S, Reed SG, Nathan C-AO, Moore MG, Day T, Judson BL. Public awareness of head and neck cancers: a cross-sectional survey. JAMA Otolaryngol Head Neck Surg. 2014;140(7):639–46. doi:10.1001/jamaoto.2014.867.
   PubMed Web of Science ®Google Scholar
• Lowy DR, Herrero R, Hildesheim A. Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging. Lancet Oncol. 2015;16(5):e226–33. doi:10.1016/S1470-2045(15)70075-6.
   PubMed Web of Science ®Google Scholar
• Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One. 2013;8(7):e68329. doi:10.1371/journal.pone.0068329.
   PubMed Web of Science ®Google Scholar
• Hirth JM, Chang M, Resto VA. Prevalence of oral human papillomavirus by vaccination status among young adults (18-30years old). Vaccine. 2017;35(27):3446–51. doi:10.1016/j.vaccine.2017.05.025.
   PubMed Web of Science ®Google Scholar
• Tota JE, Struyf F, Merikukka M, Gonzalez P, Kreimer AR, Bi D, Castellsagué X, de Carvalho NS, Garland SM, Harper DM, et al. Evaluation of type replacement following HPV16/18 vaccination: pooled analysis of two randomized trials. J Natl Cancer Inst. 2017;109(7). doi:10.1093/jnci/djx007.
   PubMedGoogle Scholar
• Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine. 2010;28(42):6858–67. doi:10.1016/j.vaccine.2010.08.030.
   PubMed Web of Science ®Google Scholar
• Eichler HG, Kong SX, Gerth WC, Mavros P, Jönsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7(5):518–28. doi:10.1111/j.1524-4733.2004.75003.x.
   PubMed Web of Science ®Google Scholar
• Blanco RG, Califano J, Messing B, Richmon J, Liu J, Quon H, Neuner G, Saunders J, Ha PK, Sheth S, et al. Transcervical ultrasonography is feasible to visualize and evaluate base of tongue cancers. PLoS One. 2014;9(1):e87565. doi:10.1371/journal.pone.0087565.
   PubMed Web of Science ®Google Scholar
• Fakhry C, Rosenthal BT, Clark DP, Gillison ML. Associations between oral HPV16 infection and cytopathology: evaluation of an oropharyngeal “pap-test equivalent” in high-risk populations. Cancer Prev Res (Phila). 2011;4(9):1378–84. doi:10.1158/1940-6207.CAPR-11-0284.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. National Library of Medicine (U.S.). HPV related oropharyngeal and uncommon cancers screening. Identifier NCT0289742; 2017 Mar 28 [accessed 2019 Jan 11]. https://clinicaltrials.gov/ct2/show/NCT02897427?id=NCT02897427&rank=1&load=cart.
   Google Scholar
• AHNS. AHNS prevention & early detection committee position statement on early detection of pre-malignant oral cancer. Council AE, Editor. American Head and Neck Society; 2017.
   Google Scholar
• Mork J, Lie AK, Glattre E, Hallmans G, Jellum E, Koskela P, Møller B, Pukkala E, Schiller JT, Youngman L, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med. 2001;344(15):1125–31. doi:10.1056/NEJM200104123441503.
   PubMed Web of Science ®Google Scholar
• Kreimer AR, Johansson M, Yanik EL, Katki HA, Check DP, Lang Kuhs KA, Willhauck-Fleckenstein M, Holzinger D, Hildesheim A, Pfeiffer R, et al. Kinetics of the human papillomavirus type 16 e6 antibody response prior to oropharyngeal cancer. J Natl Cancer Inst. 2017;109(8). doi:10.1093/jnci/djx007.
   Google Scholar
• Fakhry C, Qualliotine JR, Zhang Z, Agrawal N, Gaykalova DA, Bishop JA, Subramaniam RM, Koch WM, Chung CH, Eisele DW, et al. Serum antibodies to HPV16 early proteins warrant investigation as potential biomarkers for risk stratification and recurrence of HPV-associated oropharyngeal cancer. Cancer Prev Res (Phila). 2016;9(2):135–41. doi:10.1158/1940-6207.CAPR-15-0299.
   PubMed Web of Science ®Google Scholar
• Coquia SF, Hamper UM, Holman ME, DeJong MR, Subramaniam RM, Aygun N, Fakhry C. Visualization of the oropharynx with transcervical ultrasound. AJR Am J Roentgenol. 2015;205(6):1288–94. doi:10.2214/AJR.15.14299.
   PubMed Web of Science ®Google Scholar
• Mydlarz WK, Liu J, Blanco R, Fakhry C. Transcervical ultrasound identifies primary tumor site of unknown primary head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. 2014;151(6):1090–92. doi:10.1177/0194599814549181.
   PubMed Web of Science ®Google Scholar
• Sano Y,KM, Hamamoto Y. New diagnostic method based on color imaging using narrowband imaging (NBI) system for gastrointestinal tract. Gastrointest Endosc J. 2001;53:AB125.
   Web of Science ®Google Scholar
• Muto M, Minashi K, Yano T, Saito Y, Oda I, Nonaka S, Omori T, Sugiura H, Goda K, Kaise M, et al. Early detection of superficial squamous cell carcinoma in the head and neck region and esophagus by narrow band imaging: a multicenter randomized controlled trial. J Clin Oncol. 2010;28(9):1566–72. doi:10.1200/JCO.2009.25.4680.
   PubMed Web of Science ®Google Scholar
• Ni XG, Cheng -R-R, Lai S-Q, Zhang L, He S, Zhang Y-M, Wang G-Q. [Value of narrow band imaging endoscopy in the detection of unknown primary site with cervical lymph node metastasis of squamous cell carcinoma]. Zhonghua Zhong Liu Za Zhi. 2013;35:698–702.
   PubMedGoogle Scholar
• Hayashi T, Muto M, Hayashi R, Minashi K, Yano T, Kishimoto S, Ebihara S. Usefulness of narrow-band imaging for detecting the primary tumor site in patients with primary unknown cervical lymph node metastasis. Jpn J Clin Oncol. 2010;40(6):537–41. doi:10.1093/jjco/hyp197.
   PubMed Web of Science ®Google Scholar
• Meier JD, Xie H, Sun Y, Sun Y, Hatami N, Poirier B, Marcu L, Farwell DG. Time-resolved laser-induced fluorescence spectroscopy as a diagnostic instrument in head and neck carcinoma. Otolaryngol Head Neck Surg. 2010;142(6):838–44. doi:10.1016/j.otohns.2010.02.005.
   PubMed Web of Science ®Google Scholar
• Sun Y, Phipps JE, Meier J, Hatami N, Poirier B, Elson DS, Farwell DG, Marcu L. Endoscopic fluorescence lifetime imaging for in vivo intraoperative diagnosis of oral carcinoma. Microsc Microanal. 2013;19(4):791–98. doi:10.1017/S1431927613001530.
   PubMed Web of Science ®Google Scholar
• Chan KCA, Woo JKS, King A, Zee BCY, Lam WKJ, Chan SL, Chu SWI, Mak C, Tse IOL, Leung SYM, et al. Analysis of plasma epstein-barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med. 2017;377(6):513–22. doi:10.1056/NEJMoa1701717.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang Y, Springer S, Mulvey CL, Silliman N, Schaefer J, Sausen M, James N, Rettig EM, Guo T, et al. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci Transl Med. 2015;7(293):293ra104. doi:10.1126/scitranslmed.aad3106.
   PubMed Web of Science ®Google Scholar
• Ahn SM, Chan JYK, Zhang Z, Wang H, Khan Z, Bishop JA, Westra W, Koch WM, Califano JA. Saliva and plasma quantitative polymerase chain reaction-based detection and surveillance of human papillomavirus-related head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2014;140(9):846–54. doi:10.1001/jamaoto.2014.1338.
   PubMed Web of Science ®Google Scholar
• Hanna GJ, Supplee JG, Kuang Y, Mahmood U, Lau CJ, Haddad RI, Jänne PA, Paweletz CP. Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer. Ann Oncol. 2018;29:1980–86. doi:10.1093/annonc/mdy251.
   PubMed Web of Science ®Google Scholar